named programs · 2 · from sources
what they call their work
Cannabis and Psilocybin Clinical Trials
FDA-authorized clinical trials investigating the therapeutic potential of whole plant and fungal medicines for treatment-resistant conditions
Right to Try Program
Provides access to investigational plant and fungal medicines for patients with life-threatening conditions under federal Right to Try legislation
activities · 3
what they do
research · 3
- Clinical research on whole plant and fungal medicines Clinical Research on Schedule I SubstancesConducts ethical, federally authorized clinical research on whole plant and fungal medicines, operating under federal licensure and focusing on substances classified as Schedule I.
- Clinical research on whole plant and fungal medicines Clinical Research on Schedule I SubstancesConducts ethical, federally authorized clinical research on whole plant and fungal medicines, including Schedule I substances, to evaluate their therapeutic potential. Operates under DEA licensure for cultivation, manufacturing, and study within FDA-authorized clinical trials.
- LSD-assisted therapy study for anxiety in life-threatening illnessSponsored and conducted the first U.S. study in over 40 years on LSD's therapeutic use, specifically for anxiety in patients with life-threatening illnesses. The double-blind, randomized, active placebo-controlled pilot study with 12 participants showed statistically significant reduction in anxiety (p=0.021) at two months, with effects lasting up to 12 months and no significant adverse events.
strategies · 4
how they think
Theories of action extracted from this org's own source material. Click any approach shared with other orgs to see the full field.
- Advance evidence-based plant and psychedelic therapies through research and policy evidence-based alternative therapies unique to this orgExpands access to evidence-based alternative therapies like cannabis and psilocybin by conducting rigorous scientific research, influencing public policy, and implementing innovative access programs such as Right to Try, with the goal of integrating these treatments into mainstream healthcare.
- Advancing evidence-based alternative therapies for treatment-resistant conditions evidence_based_alternative_therapies unique to this orgThe organization expands access to and explores the therapeutic potential of naturally derived compounds, such as cannabis and psilocybin, through scientifically rigorous research, public policy engagement, and innovative access programs like Right to Try. This approach aims to address treatment-resistant conditions, particularly among veterans and underserved communities, by bridging traditional healthcare systems and emerging plant-based therapeutics with transparency, scientific integrity, and patient advocacy.
- Investigate LSD-assisted therapy for end-of-life anxiety LSD-assisted therapy unique to this orgConducts clinical research on LSD-assisted therapy to evaluate its safety and effectiveness in reducing anxiety among individuals facing life-threatening illnesses, contributing to the broader evidence base for psychedelic-assisted treatments.
- Target treatment-resistant conditions in underserved populations using naturally derived compounds exploring therapeutic potential of naturally derived compounds unique to this orgFocuses on addressing treatment-resistant conditions—particularly in veterans and underserved communities—by researching the therapeutic potential of naturally derived compounds, including psychedelics and cannabinoids, to improve access and outcomes for those failed by conventional medicine.
financials · form 990EZ · fy2022
the money
revenue
Total revenue$122K
Contributions & grants$122K100%
Program service revenue$00%
Investment income$00%
Other revenue$0
expenses
Total expenses$102K
Program expenses—
Admin / overhead—
Fundraising—
Salaries & benefits$0
Grants paid out$0
balance sheet
Total assets$37K
Cash—
Investments—
Liabilities—
Net assets$37K
1 years on record · 2022–2022
leadership · form 990 part vii · fy2022
who runs it
board members · 2
- John Lenstrohm — Director
- Kendric Speagle — Director